ESMO 2023: Adding a PARP Inhibitor to Chemoimmunotherapy in Advanced Endometrial Cancer
Posted: 11/22/2023 | By: Chase Doyle

Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer. DUO-E evaluated the addition of durvalumab to standard first-line carboplatin/paclitaxel, followed by maintenance durvalumab with or without olaparib, in patients with advanced endometrial cancer. Results were presented at the ESMO Congress 2023 (Abstract LBA41) and simultaneously published in the Journal of Clinical Oncology.

Question 1 of 5

What is the standard of care for newly diagnosed advanced or recurrent endometrial cancer?

Choose 1